Last reviewed · How we verify
ABT-888
ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes.
ABT-888 is a PARP inhibitor that works by blocking the action of poly (ADP-ribose) polymerase (PARP) enzymes. Used for Metastatic breast cancer, triple-negative breast cancer, ovarian cancer.
At a glance
| Generic name | ABT-888 |
|---|---|
| Also known as | ABT-888, veliparib, veliparib, Veliparib |
| Sponsor | AbbVie (prior sponsor, Abbott) |
| Drug class | PARP inhibitor |
| Target | PARP |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting PARP enzymes, ABT-888 prevents DNA repair in cancer cells, leading to cell death. This mechanism is particularly effective in cancers with homologous recombination repair deficiencies.
Approved indications
- Metastatic breast cancer, triple-negative breast cancer, ovarian cancer
Common side effects
- Nausea
- Vomiting
- Fatigue
- Diarrhea
- Anemia
Key clinical trials
- Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction (PHASE1)
- Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia (PHASE2)
- Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme (PHASE2, PHASE3)
- Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery (PHASE1, PHASE2)
- Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma (PHASE1)
- Cyclophosphamide and Veliparib in Treating Patients With Locally Advanced or Metastatic Breast Cancer (PHASE1)
- Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations (PHASE2)
- Veliparib and Dinaciclib in Treating Patients With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABT-888 CI brief — competitive landscape report
- ABT-888 updates RSS · CI watch RSS
- AbbVie (prior sponsor, Abbott) portfolio CI